Tolerability of Rofecoxib versus Naproxen
Authors: M. L. Jenkinson
Journal: Annals of Internal Medicine (2004)

Letters15 June 2004Tolerability of Rofecoxib versus NaproxenM. L. Jenkinson, FRCPM. L. Jenkinson, FRCPFrom Queen Elizabeth the Queen Mother Hospital, Kent CT9 4AN, United Kingdom.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-12-200406150-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:If Lisse and colleagues (1) reported a completely new data set, it would be possible to perform a meta-analysis of their data set and that of the Vioxx Gastrointestinal Outcomes Research (VIGOR) study (2). On an intention-to-treat basis, Lisse and colleagues showed that rofecoxib does not statistically differ from naproxen in rates of withdrawal for clinical and laboratory adverse events combined. Therefore, to make up for rofecoxib's better GI tolerability, other adverse events must have occurred. One was myocardial infarction.In the intention-to-treat analysis, 5 of 2799 patients in the rofecoxib group and 1 of 2787 patients ...References1. Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, et al . Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med. 2003;139:539-46. [PMID: 14530224] LinkGoogle Scholar2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-8. [PMID: 11087881] CrossrefMedlineGoogle Scholar3. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, et al . Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104:2280-8. [PMID: 11696466] CrossrefMedlineGoogle Scholar4. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573-4. [PMID: 12598144] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: M. L. Jenkinson, FRCPAffiliations: From Queen Elizabeth the Queen Mother Hospital, Kent CT9 4AN, United Kingdom. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoGastrointestinal Tolerability and Effectiveness of Rofecoxib versus Naproxen in the Treatment of Osteoarthritis Jeffrey R. Lisse , Monica Perlman , Gunnar Johansson , James R. Shoemaker , Joy Schechtman , Carol S. Skalky , Mary E. Dixon , Adam B. Polis , Arthur J. Mollen , Gregory P. Geba , and Tolerability of Rofecoxib versus Naproxen Jeffrey R. Lisse , Monica Perlman , Adam B. Polis , and Gregory P. Geba Tolerability of Rofecoxib versus Naproxen Lonnie B. Hanauer Tolerability of Rofecoxib versus Naproxen John M. Rusche Metrics 15 June 2004Volume 140, Issue 12Page: 1059-1060KeywordsAdverse eventsAspirinIbuprofenIntent to treat analysisMyocardial infarctionNSAIDsRelative riskResearch laboratoriesSafetyStatistical data ePublished: 15 June 2004 Issue Published: 15 June 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...